Bionano Genomics (MEX:BNGO) Stock Based Compensation: MXN66.4 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:BNGO Bionano Genomics Inc MEX:BNGO
62 GF Score
Price MXN19.09
GF Value MXN27.19
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Bionano Genomics Stock Based Compensation?

Bionano Genomics MEX:BNGO 62 Stock Based Compensation is MXN66.4 Mil as of Mar. 2026. GuruFocus rates MEX:BNGO with a GF Score™ of 62/100 and a GF Value™ of MXN27.19 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Bionano Genomics's Stock Based Compensation for the three months ended in Mar. 2026 was MXN12.1 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was MXN66.4 Mil.

Bionano Genomics Stock Based Compensation Related Terms

Bionano Genomics Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Bionano Genomics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bionano Genomics Stock Based Compensation Chart

Bionano Genomics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 199.38 437.04 257.64 203.05 81.64

Bionano Genomics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.47 20.34 17.26 16.67 12.08
MEX:BNGO
62GF Score
Bionano Genomics Inc MEX:BNGO
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bionano Genomics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN66.4 Mil.

What does a Stock Based Compensation of MXN66.4 Mil mean?
Bionano Genomics (MEX:BNGO) has a Stock Based Compensation of MXN66.4 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Bionano Genomics and its competitors.
Is Bionano Genomics' Stock Based Compensation too high?
Bionano Genomics' current Stock Based Compensation is MXN66.4 Mil. Overall, Bionano Genomics has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bionano Genomics' Stock Based Compensation compare to RGNT and UEEC?
Bionano Genomics' Stock Based Compensation of MXN66.4 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Medical Devices & Instruments company?
A good Stock Based Compensation depends on the Medical Devices & Instruments industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Bionano Genomics and its competitors. Bionano Genomics's current Stock Based Compensation is MXN66.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionano Genomics stock overvalued right now?
Based on GuruFocus' analysis, Bionano Genomics (MEX:BNGO) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN27.19, compared to a current price of MXN19.09 — trading 29.8% below its estimated fair value. The current Stock Based Compensation is MXN66.4 Mil. Bionano Genomics' overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Bionano Genomics (MEX:BNGO), the current Stock Based Compensation is MXN66.4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bionano Genomics (MEX:BNGO) Overvalued in 2026?

Based on GuruFocus' analysis, Bionano Genomics stock appears to be undervalued. The current stock price of MXN19.09 is trading 29.8% below its estimated GF Value™ of MXN27.19. GuruFocus considers Bionano Genomics to be Modestly Undervalued.

Key valuation signals for MEX:BNGO:

  • Stock Based Compensation: MXN66.4 Mil
  • GF Value™: MXN27.19 vs. price of MXN19.09 (29.8% below fair value)
  • GF Score™: 62/100 with 3 warning signs

No single metric tells the full story. See the MEX:BNGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bionano Genomics Business Description

Other Exchanges BNGO:USA
Address 9540 Towne Centre Drive, Suite 100, San Diego, CA, USA, 92121
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.
62GF Score

Get the complete analysis for MEX:BNGO

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN19.09
Price
MXN27.19
GF Value